COMP <GO>
ORKA vs UNH // PIOTROSKI F-SCORE QUALITY
Oruka Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ORKA 3
— UNH 11
▲ PIOTROSKI F-SCORE QUALITY LEADER: UNH
LAST: $96.87 (+0.23%) • MKT CAP: $6.40B
piotroski-score
4/9
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORKA VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORKA | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.80% | 11.47% | -30.27 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | 6.48% | -7.86 | UNH | /fcf-yield <GO> |
| Operating Margin | -6.80% | 4.82% | -11.62 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.90% | 3.14% | -9.04 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -4.40% | 6.46% | -10.86 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | ORKA | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.74% | +0.56 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 56.0 | +11.13 | ORKA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.33 | +0.80 | ORKA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 17.1x | +10.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.40B | $364.66B | -$358.26B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORKA REV | UNH REV | ORKA GROSS % | UNH GROSS % | ORKA FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | -$88.4M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | -$58.0M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$5.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORKA // BETA 1.13
UNH // BETA 0.33